Point Therapeutics to Present at Friedman Billings Ramsey 2006 Growth Investor Conference

Point Therapeutics, Inc. (NASDAQ:POTP) announced that
Don Kiepert, President and CEO, will present at the Friedman Billings
Ramsey 2006 Growth Investor Conference at the Grand Hyatt Hotel in New
York City on Thursday, June 1, 2006 at 9:00 a.m. Eastern Time. Mr.
Kiepert will review key research and development accomplishments and
discuss upcoming corporate initiatives. A live Web cast of the
presentation will be available on the Company's Web site,
www.pther.com.

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.